AVADEL PHARMACEUTICALS PLC
CIK:
0001012477
Company Information
Industry
Pharmaceutical Preparations
SIC Code
2834
Entity Type
operating
SEC Category
Large accelerated filer
Country
Ireland
Business Address
10 EARLSFORT TERRACE, DUBLIN 2, , D02 T380
Mailing Address
16640 CHESTERFIELD GROVE ROAD, CHESTERFIELD, MO, 63005
Phone
636-449-1830
Fiscal Year End
1231
EIN
000000000
Financial Overview
FY2024
-$48.83M
Net Income
$164.70M
Total Assets
$90.39M
Total Liabilities
$78.24M
Stockholders' Equity
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| 4 Insider stock transaction report | February 18, 2026 | View on SEC |
| 3 Initial insider ownership report | February 18, 2026 | View on SEC |
| SCHEDULE 13G/A Passive ownership amendment | February 17, 2026 | View on SEC |
| SCHEDULE 13G/A Passive ownership amendment | February 17, 2026 | View on SEC |
| 4 Insider stock transaction report | February 12, 2026 | View on SEC |
| SCHEDULE 13G/A Passive ownership amendment | February 12, 2026 | View on SEC |
| 4 Insider stock transaction report | February 12, 2026 | View on SEC |
| 4 Insider stock transaction report | February 12, 2026 | View on SEC |
| 4 Insider stock transaction report | February 12, 2026 | View on SEC |
| 8-K Current report of material events | February 12, 2026 | View on SEC |
Material Events
8-K
Acquisition
February 12, 2026
High Impact
- AVADEL PHARMACEUTICALS PLC was acquired by Alkermes plc, ending its independent public trading status.
- Former shareholders received $21.00 in cash per share, plus a Contingent Value Right (CVR) for a potential additional $1.50 per share.
8-K
Acquisition
January 20, 2026
High Impact
- Avadel Pharmaceuticals is nearing acquisition by Alkermes plc, integrating its FDA-approved narcolepsy treatment, Lumryz, into Alkermes' neuroscience portfolio.
- Lumryz is expected to become a significant growth driver and revenue source for Alkermes.
8-K
Acquisition
January 12, 2026
High Impact
- AVADEL shareholders overwhelmingly approved the acquisition by Alkermes plc.
- Over 95% of voting shareholders supported the main acquisition scheme.
Insider Trading
SELL
1 insiders
1 recent transactions
View Full Insider Trading Profile
Related Companies
Companies in the same industry (SIC: 2834)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.